EGFR and squamous cell carcinoma of penis: Additionally, a separate phase II trial (NCT04475016) is testing triprilimab (anti–PD–1) combined with nimotuzumab (anti-EGFR) and TIP chemotherapy in patients with locally advanced PSCC.